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Data (attached) for a focused review and meta-analysis of cerebral
levels of glutamate, Glx, and GABA levels assessed with 1H-MRS in
high-risk of psychosis states [1] was collected and stored at
covidence.org and extracted to The Cochrane Collaboration
Review Manager software package (RevMan Version 5.3) for meta-
analytical purposes. Meta-analyses were performed with a random-
effects, inverse-variance weighted model to calculate the pooled ef-
fect size. Heterogeneitywasmeasured using the I2 value. Significance
was assessed using two-sided 95% confidence intervals. Potential
publication bias was assessed by visual inspection of funnel plots.
Supplementary to the co-submitted article are comprehensivemeta-
analyses of glutamate, Glx, and GABA, as well as the PRISMA flowj.schres.2019.10.050.
enter for Mental Health, CORE, Mental Health Center Copenhagen, Copen-
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File I includes comprehensive meta-analyses for glutamate, Glx, and GABA as well as subgroup
analyses according to the type of study (e.g., clinical or genetic high-risk; study performed on
antipsychotic naïve participants or not).
Fig. 1 depicts the PRISMA flow diagram of the included studies.
Table 1 lists the studies included in the review as well as all available measures and methodological
variables.
Fig. 2 shows the meta-analysis and forest plot of all glutamate and Glx studies included in the
review combined (including Glx measures for studies not reporting glutamate).
Fig. 3 depicts the funnel plot of comparisons for studies included in the review for glutamate, Glx,
and GABA, respectively, to assess signs of asymmetry reflecting possible publication bias.
File II includes raw data of glutamate, Glx, and GABA levels for all included studies as well as author
information and a range of demographical and clinical data extracted from the studies.
2. Experimental design, materials, and methods
The associated review and meta-analysis [1] was designed to establish whether there is any dif-
ference in baseline glutamate or GABA levels in individuals at high risk of developing psychosis (clinical479 references imported for
screening
393 studies screened against 
?tle and abstract
105 studies assessed for full-
text eligibility
28 studies included
77 studies excluded*
288 studies excluded
86 duplicates removed
*Reasons for study exclusion:
52 conference papers
8 reviews or meta-analyses
7 duplicates
5 results reported in other study
3 wrong outcomes
1 correspondence
1 design paper
Fig. 1. PRISMA flow diagram of literature search and study selection.
Table 1
List of studies included in the review, available measures and methodological variables.
Study and Year High-risk group Region Voxel size (cm) Metabolite Field
strength
(T)
Acquisition
sequence
Echo time
(ms)
Correction
method
Mean (SD)
in article
Block 2000 GHR Left frontal lobe 4.0  3.0  2.5 Glx 1.5 PRESS 30 Cr scaling Yes
Basal ganglia 3.5  3.5  2.0
Bloemen 2011 UHR Left hippocampus 2  2  2 Glu 3 PRESS 36 Not stated Yes
Byun 2009 UHR with MDD ACC 2  2  2 Glx 1.5 PRESS 40 CSF Yes
UHR without MDD Left DLPFC
Left thalamus
Capizzano 2011 GHR (1rst degree
relative)
ACC 8 cm3 Glx 3 PRESS 30 Cr scaling Yes
GHR (2nd degree
relative)
Left hippocampus 4.5 cm3
Da Silva 2018 CHR MPFC 2  4  3 GABA 3 MEGA-PRESS 68 Not stated Provided by author
de la Fuente-
Sandoval 2011
UHR Dorsal caudate 2  2  2 Glu, Glx 3 PRESS 35 CSF Yes
Cerebellum
de la Fuente-
Sandoval 2015
UHR MPFC 3.0  2.5  2.5 Glx, GABA 3 MEGA-PRESS 68 CSF Yes
Dorsal caudate 4.5  2.5  2.0
Egerton 2014 UHR Left thalamus 1.5  2.0  2.0 Glu, Glx 3 PRESS 30 CSF Yes
ACC 2  2  2
Grent-'t-Jong 2018 CHR Right MOG 2  2  2 GABA, Glx 3 MEGA-PRESS 68 Cr scaling Raw data available
Keshavan 2009 GHR Caudate 4.5cm3 Glx 1.5 PRESS 30 CSF Estimated
Liemburg 2016 UHR Left LPFC 2  2  2 Glx 1.5 PRESS 144 CSF Estimated
Lutkenhoff 2007 GHR mesPFC 2  2  2 Glu 3 PRESS 30 CSF Yes
L-PFWM 2  2  2
Left hippocampus 1.5  1.5  1.5
Marenco 2016 GHR ACC 2  2  4.5 GABA 3 MEGA-PRESS 68 CSF Provided by author
Menschikov 2016 UHR-S ACC 3  3  3 GABA, Glx 3 MEGA-PRESS 68 Cr scaling Provided by author
Modinos 2018 UHR MPFC 4.0  3.5  2.0 GABA, Glu. Glx 3 MEGA-PRESS 68 Cr scaling Corrected values
provided by author
Natsubori 2013 UHR MPFC 2  2  2 Glx 3 STEAM 15 CSF Yes
Nenadic 2015 UHR Right hippocampus 3  1  1 Glu 3 PRESS 30 CSF Yes
Left hippocampus
Purdon 2007 GHR MFC 2.5  2.5  2.5 Glu, Glx 3 STEAM 20 Cr scaling Yes
Shakory 2018 CHR Left hippocampus 3.0  1.4  1.0 Glu, Glx 3 PRESS 35 CSF Estimated
3.0  1.4  1.0
Shendyapina 2015 CHR DLPC ? Glx 3 PRESS 35 Not stated Not given
Left thalamus
Right thalamus
Stone 2009 ARMS ACC 2  2  2 Glu, Gln, Glx 3 PRESS 30 CSF Yes
Left hippocampus 2.0  2.0  1.5
Left thalamus 1.5  2.0  2.0
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Tandon 2013 GHR Thalamus 1.5  1.5  2.0 Glx 1.5 PRESS 30 CSF Yes
Caudate 1.5  1.5  2.0
ACC 1.5  1.5  2.0
Thakkar 2017 GHR Occipital cortex 4.0  2.4  2.5 GABA,
Glu, Gln, Glx
7 MEGA-
sLASER
36 Cr scaling Yes
Right striatum 4.0  2.4  2.5
Left striatum 4.0  2.4  2.5
Tibbo 2004 GHR Right MFC 2.5cm3 Glx 3 STEAM 20 Cr scaling Yes
Valli 2011 ARMS Medial temporal
cortex
2.0  2.0  1.5 Glu 3 PRESS 30 CSF Yes
ACC 2  2  2
Thalamus 1.5  2.0  2.0
Wang 2016 UHR MPFC 3  3  3 GABA, Glx 3 MEGA-PRESS 68 CSF Estimated
Wood 2010 UHR-P Temporal lobe ? Glx 3 PRESS 30 Not stated Yes
UHR-NP
Yoo 2009 HGR (two
relatives w. scz.)
ACC 2  2  2 Glx 1.5 PRESS 140 CSF Yes
DLPC 2.0  1.5  2.0
Thalamus 1.5  2.0  2.0
Abbreviations: T, Tesla; GHR, genetic high risk; UHR, ultra-high risk; MDD, major depressive disorder; CHR, clinical high risk; ARMS, at-risk mental state; UHR-P, UHRwith transition; UHR-
NP, UHR without transition; HGR, high genetic risk; scz., schizophrenia; ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; MPFC, medial prefrontal cortex; MOG, middle
occipital gyrus; LPFC, lateral prefrontal cortex; MPFC, medial prefrontal cortex; PFWM, prefrontal white matter; Glx, combinedmeasures of glutamate and glutamine; Glu, glutamate; GABA,
gamma aminobutyric acid; PRESS, Point resolved spectroscopy; MEGA-PRESS, MeshchereGarwood point resolved spectroscopy; STEAM, stimulated echo acquisition mode; Cr, creatine;
CSF, cerebrospinal fluid.
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Fig. 3. Funnel plot of comparison for studies included in the review. Top row left to right: Glutamate, Glx. Bottom row: GABA.
Abbreviations: Glx, combined measures of glutamate and glutamine; GABA, gamma aminobutyric acid.
C. Wenneberg et al. / Data in brief 28 (2020) 104920 7or genetic high-risk states) compared to healthy controls as measured with 1H-MRS (levels of cerebral
glutamate (glutamate, glutamine, or Glx) and/or GABA measured by applying a voxel of interest in a
cerebral region) where HR and healthy controls are being compared.
High-risk states included clinical high risk as measured by clinical assessment tools (e.g., CAARMS,
SIPS, or SOPS) as well as genetic high risk (having a relative with a psychotic disorder).
Embase and MEDLINE databases were searched for all relevant case/control studies without re-
strictions on language, year, or publication status. Studies fulfilling the search strategy were included
search terms: (Ultra high risk or Genetic high risk or Clinical high risk or High risk) and (Glutamate*
or GABA* or Neurotransmitter*) and (MRS or Spectroscopy or MR* or Magnetic resonance spec-
troscopy or 1H-MRS). If more than one scan was done in the same population, we only included the
baseline values.
Reference lists of included studies and reviews were searched manually for additional studies, and
clinicaltrials.gov were searched for ongoing or unpublished studies, and the responsible researchers
were contacted and asked to share potential unpublished data. We received no unpublished data.
We excluded studies with no comparison group or with the wrong comparison group (e.g., not
healthy controls such as patients with schizophrenia or first-episode psychosis) as well as studies with
previously published results.
The first search was performed on March 10th, 2019, and the final search was performed on April
9th, 2019, where no new eligible studies were found.Fig. 2. Meta-analysis of all glutamate and Glx studies included in the meta-analysis combined (including Glx measures for studies
not reporting glutamate). Forest plot showing standardized mean differences for 1H-MRS glutamate studies in high-risk versus
controls. Error bars represent 95% confidence intervals. Abbreviations: 1H-MRS, proton magnetic resonance spectroscopy.
C. Wenneberg et al. / Data in brief 28 (2020) 1049208Two researchers performed the literature search (CWand FZ). Titles and abstracts screening, as well
as full-text screening, were done independently by the two above mentioned researches. Any dis-
agreements between the two independent assessors were resolved through discussion, with CW
having the final word. Data from each study were independently extracted from the included studies
by CWand FZ. CW compared the extracted data and determined the consensus. We used covidence.org
for importing studies, title and abstracts screening, full-text screening, and for extracting and storing
the data. Primary data extractedwere available metabolite levels of GABA, Glx, glutamate, or glutamine
measured by 1H-MRS. Risk of bias assessment of included studies was performed using the Newcastle-
Ottawa scale.
Datawere subsequently exported to The Cochrane Collaboration ReviewManager software package
(RevMan Version 5.3) were meta-analyses were performed using a random-effects, inverse-weighted
variance model to calculate the pooled effect size since studies were expected to display high het-
erogeneity based on different correction methods, varying regions of interest, and diverse high-risk
groups. The study effect size was weighted according to sample size. Heterogeneity was measured
using the I2 value, with higher percentages signifying higher variation across studies in the meta-
analysis. Significance was assessed using two-sided 95% confidence intervals.
Meta-analyses were performed separately for mean values of GABA, glutamate, and Glx (only two
studies reported glutamine levels; hence, no meta-analysis was performed for this metabolite). If
means or standard deviations were not published or only reported in figures, authors were contacted
for this information. If we did not receive a response, means and SDs were estimated from represented
figures using WebPlotDigitizer ordif not shown in figuresdnot included in the meta-analysis (Table 1
provides more detail on this). Potential publication bias was assessed by visual inspection of funnel
plots for studies on glutamate, Glx, and GABA, respectively (Fig. 3).
Each metabolite results was sorted into relevant subdomains of the brain ((1)frontal lobe, voxels
placed in the anterior cingulate cortex (ACC), the medial prefrontal cortex (MPFC), or the dorsolateral
prefrontal cortex (DLPFC); (2)the occipital lobe; (3)the temporal lobe; (4)hippocampus; (5)striatum,
including basal ganglia and caudate; (6)thalamus; (7)cerebellum; and (8)white matter). Measures
were not available for all regions for all metabolites. Each study was only represented once in each
subdomain. For studies reporting subgroups of high-risk states with a shared control group, measures
were treated as separate data sets, and the number of healthy controls was divided by the number of
subgroups (always two). In studies where bilateral measures were provided, measures from the left
side were included in the analyses.
When the number of studies allowed (more than two studies available), subgroup analyses were
performed based on high-risk status, treatment with antipsychotic medication, and location of the
voxel of interest in the frontal lobe.
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